Rob Filip, Hercogová Jana
a Dermatovenereology Department , Na Bulovce Hospital, 2nd Medical Faculty Charles University , Prague , Czech Republic.
J Dermatolog Treat. 2018 Feb;29(1):39-43. doi: 10.1080/09546634.2017.1329507. Epub 2017 May 30.
To evaluate effectivity, safety and patients' adherence to benzathine penicillin G (BPG) 1,200,000 units (1.2 MU) once-every-3-week intramuscularly prophylaxis for recurrent erysipelas.
Patients with documented two or more erysipelas episodes in last two years who received at least one of 10 planned doses of BPG 1.2 MU intramuscularly between January 2009 and December 2015 were analyzed in this retrospective study. Number of recurrences during the 30-week prophylaxis and in the 30-week follow-up period, frequency of adverse events, patients' adherence to the treatment and factors associated with the recurrence were analyzed.
From 132 patients, 109 (82.6%) finished the 30-week prophylactic regimen successfully. The incidence of erysipelas was 8 per 100 patient-years during the prophylactic period and 28 per 100 patient-years in the follow-up period (incidence rate ratio = 0.20; 95% CI: 0.05-0.34; p < .01). In univariate analysis recurrence was significantly associated only with presence of any local risk factor concurrently with obesity (OR 3.40; 95% CI: 1.10-10.50; p < .05).
Benzathine penicillin G 1.2 MU once every 3 weeks is an effective and well-tolerated prophylaxis of recurrent erysipelas with good patient adherence to the treatment. Further studies to determine the appropriate duration of prophylaxis are necessary.
评估苄星青霉素G（BPG）120万单位（1.2MU）每3周肌内注射一次预防复发性丹毒的有效性、安全性及患者依从性。
本回顾性研究分析了2009年1月至2015年12月期间有记录表明在过去两年中发生过两次或更多次丹毒发作且接受了至少10剂计划中的1.2MU BPG肌内注射的患者。分析了30周预防期和30周随访期内的复发次数、不良事件发生频率、患者对治疗的依从性以及与复发相关的因素。
132例患者中，109例（82.6%）成功完成了30周的预防方案。预防期丹毒发病率为每100患者年8例，随访期为每100患者年28例（发病率比值=0.20；95%CI：0.05 - 0.34；p<0.01）。单因素分析显示，复发仅与肥胖同时存在任何局部危险因素显著相关（OR 3.40；95%CI：1.10 - 10.50；p<0.05）。
每3周一次肌内注射1.2MU苄星青霉素G是预防复发性丹毒的一种有效且耐受性良好的方法，患者对治疗的依从性良好。有必要进一步研究确定合适的预防持续时间。
